These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 33413474)

  • 21. Impact of KRAS mutation on the tumor microenvironment in colorectal cancer.
    Zhou Y; Kuang Y; Wang C; Yu Y; Pan L; Hu X
    Int J Biol Sci; 2024; 20(5):1947-1964. PubMed ID: 38481800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.
    Tarpgaard LS; Ørum-Madsen MS; Christensen IJ; Nordgaard C; Noer J; Guren TK; Glimelius B; Sorbye H; Ikdahl T; Kure EH; Tveit KM; Nielsen HJ; Pfeiffer P; Brünner N; Moreira JM
    Oncotarget; 2016 Sep; 7(37):59441-59457. PubMed ID: 27509063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer.
    Lal N; White BS; Goussous G; Pickles O; Mason MJ; Beggs AD; Taniere P; Willcox BE; Guinney J; Middleton GW
    Clin Cancer Res; 2018 Jan; 24(1):224-233. PubMed ID: 29061646
    [No Abstract]   [Full Text] [Related]  

  • 24. Molecular Profiling Provides Clinical Insights Into Targeted and Immunotherapies as Well as Colorectal Cancer Prognosis.
    Guo L; Wang Y; Yang W; Wang C; Guo T; Yang J; Shao Z; Cai G; Cai S; Zhang L; Hu X; Xu Y
    Gastroenterology; 2023 Aug; 165(2):414-428.e7. PubMed ID: 37146911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
    Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S
    J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
    Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P
    BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship of KRAS expression with KRAS status, prognosis, and tumor-infiltrated T lymphocytes in colorectal cancer.
    Zhou Y; Zeng Z; Li Z; Ruan L; Xie H; Ye F; Huang L; Liu H; Kang L
    Therap Adv Gastroenterol; 2024; 17():17562848241249387. PubMed ID: 38757097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
    Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
    Deming DA; Cavalcante LL; Lubner SJ; Mulkerin DL; LoConte NK; Eickhoff JC; Kolesar JM; Fioravanti S; Greten TF; Compton K; Doyle AG; Wilding G; Duffy A; Liu G
    Invest New Drugs; 2016 Apr; 34(2):168-75. PubMed ID: 26666244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutant KRAS Drives Immune Evasion by Sensitizing Cytotoxic T-Cells to Activation-Induced Cell Death in Colorectal Cancer.
    Liu H; Liang Z; Cheng S; Huang L; Li W; Zhou C; Zheng X; Li S; Zeng Z; Kang L
    Adv Sci (Weinh); 2023 Feb; 10(6):e2203757. PubMed ID: 36599679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.
    Gao J; Wu H; Wang L; Zhang H; Duan H; Lu J; Liang Z
    BMJ Open; 2016 Jan; 6(1):e009532. PubMed ID: 26747035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The current understanding on the impact of KRAS on colorectal cancer.
    Meng M; Zhong K; Jiang T; Liu Z; Kwan HY; Su T
    Biomed Pharmacother; 2021 Aug; 140():111717. PubMed ID: 34044280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of
    Zhang M; Wang HZ; Li HO; Zhou YJ; Peng RY; Liu J; Zhao Q
    DNA Cell Biol; 2020 Sep; 39(9):1639-1648. PubMed ID: 32552000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
    Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
    Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The response of PIK3CA/KRAS-mutant colorectal cancer stem-like cells to RGD-peptide FraC produced by the strawberry anemone: A promising water-soluble peptide-based inhibitor of metastasis-driver gene CXCR4, stem cell regulatory genes and self-renewal.
    Sarkhosh-Inanlou R; Imani M; Sam MR
    Biomed Pharmacother; 2020 Dec; 132():110807. PubMed ID: 33068939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis.
    Kwak MS; Cha JM; Yoon JY; Jeon JW; Shin HP; Chang HJ; Kim HK; Joo KR; Lee JI
    Medicine (Baltimore); 2017 Sep; 96(35):e7882. PubMed ID: 28858102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
    Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
    FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.
    Hayama T; Hashiguchi Y; Okamoto K; Okada Y; Ono K; Shimada R; Ozawa T; Toyoda T; Tsuchiya T; Iinuma H; Nozawa K; Matsuda K
    Int J Colorectal Dis; 2019 Aug; 34(8):1491-1496. PubMed ID: 31309326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.